Free Trial

Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

Becton, Dickinson and Company logo
$189.06 -4.87 (-2.51%)
Closing price 03:59 PM Eastern
Extended Trading
$189.20 +0.14 (+0.07%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
9
Buy
3

Based on 12 Wall Street analysts who have issued ratings for Becton, Dickinson and Company in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 9 have given a hold rating, and 3 have given a buy rating for BDX.

Consensus Price Target

$205.40
8.64% Upside
According to the 12 analysts' twelve-month price targets for Becton, Dickinson and Company, the average price target is $205.40. The highest price target for BDX is $241.00, while the lowest price target for BDX is $184.00. The average price target represents a forecasted upside of 8.64% from the current price of $189.06.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Becton, Dickinson and Company and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BDX Analyst Ratings Over Time

TypeCurrent Forecast
10/9/24 to 10/9/25
1 Month Ago
9/9/24 to 9/9/25
3 Months Ago
7/11/24 to 7/11/25
1 Year Ago
10/10/23 to 10/9/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
8 Buy rating(s)
Hold
9 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$205.40$211.44$219.22$282.63
Forecasted Upside8.64% Upside10.96% Upside24.65% Upside18.65% Upside
Consensus RatingHoldHoldHoldBuy

BDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Becton, Dickinson and Company Stock vs. The Competition

TypeBecton, Dickinson and CompanyMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.33
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside8.64% Upside1,057.15% Upside172.89% Upside
News Sentiment Rating
Positive News

See Recent BDX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/8/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C-)
9/25/2025Royal Bank Of Canada
3 of 5 stars
Shagun Singh
Not Rated
Initiated CoverageSector Perform$211.00+13.49%
9/15/2025Argus
4 of 5 stars
 Boost Target$220.00 ➝ $230.00+22.13%
8/11/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$196.00 ➝ $197.00+3.26%
8/8/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$172.00 ➝ $184.00-4.18%
8/8/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$185.00 ➝ $200.00+6.68%
6/3/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$261.00 ➝ $241.00+42.38%
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold$217.00 ➝ $185.00+6.78%
5/2/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$280.00 ➝ $224.00+34.05%
5/2/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral$192.00+13.24%
5/2/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform
5/1/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyNeutral$190.00+8.61%
5/1/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformMarket Perform
10/1/2024Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOutperform$286.00 ➝ $290.00+20.29%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:53 PM ET.


Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 7, 2025. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

Becton, Dickinson and Company
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

  • The current stock price is around $187.50, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Becton, Dickinson and Company has a strong dividend yield of approximately 2.1%, providing a steady income stream for investors.
  • Recent analyst upgrades, including a price target increase from Wells Fargo, indicate positive sentiment and potential for stock appreciation.
  • The company has a solid earnings forecast, with analysts predicting earnings per share of 14.43 for the current year, suggesting robust financial performance.
  • Insider trading activity shows confidence in the company, with recent sales by executives indicating a strategic repositioning rather than a lack of faith in the company's future.

Becton, Dickinson and Company
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

  • Insider sales have resulted in a decrease in their positions, which could signal potential concerns about the company's short-term performance.
  • The company's dividend payout ratio is relatively high at 74.82%, which may limit its ability to reinvest in growth opportunities.
  • Despite recent upgrades, the consensus rating remains a "Hold," indicating that many analysts are cautious about the stock's near-term prospects.
  • Recent insider sales have totaled over 3,000 shares, which could raise red flags for potential investors regarding the executives' confidence in the company's future.
  • Market volatility and economic uncertainties could impact the healthcare sector, potentially affecting Becton, Dickinson and Company's performance.

BDX Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Becton, Dickinson and Company is $205.40, with a high forecast of $241.00 and a low forecast of $184.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BDX, but not buy additional shares or sell existing shares.

According to analysts, Becton, Dickinson and Company's stock has a predicted upside of 8.64% based on their 12-month stock forecasts.

Over the previous 90 days, Becton, Dickinson and Company's stock had 1 upgrade by analysts.

Becton, Dickinson and Company has been rated by research analysts at Argus, Morgan Stanley, Piper Sandler, Royal Bank Of Canada, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Becton, Dickinson and Company less than other "medical" companies. The consensus rating score for Becton, Dickinson and Company is 2.25 while the average consensus rating score for "medical" companies is 2.33. Learn more on how BDX compares to other companies.


This page (NYSE:BDX) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners